Tuesday, September 17, 2024

Revenue in the Blood Glucose Monitoring Devices Market Set to Surge Twofold, $52.46 Billion Worth of Opportunities Anticipated in the Next 6 Years - Arizton Advisory & Intelligence

Revenue in the Blood Glucose Monitoring Devices Market Set to Surge Twofold, $52.46 Billion Worth of Opportunities Anticipated in the Next 6 Years - Arizton Advisory & Intelligence
The global blood glucose monitoring devices market was valued at USD 25.62 billion in 2023 and is expected to reach USD 52.46 billion by 2029, growing at a CAGR of 12.69% during the forecast period.​
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

   

According to Arizton’s latest research report, the global blood glucose monitoring devices market (BGM) is growing at a CAGR of 12.69% during 2023-2029.

   

Looking for More Information? Click: https://www.arizton.com/market-reports/blood-glucose-monitoring-devices-market-2024

 

Report Scope:   

Market Size (2029): $52.46 Billion       

Market Size (2023): $25.62 Billion       

CAGR (2023-2029): 12.69%        

Historic Year:  2020-2022           

Base Year: 2023           

Forecast Year: 2024-2029           

Market Segmentation: Product Type, Conventional Blood Glucose Monitoring Devices, Continuous Glucose Monitoring (CGM) Devices, Usage, Distribution Channel, End-Users, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa   

   

Book the Free Sample Now: https://www.arizton.com/market-reports/blood-glucose-monitoring-devices-market-2024

 

Flash Glucose Monitoring: An Emerging Trend in BGM Devices Market

Flash glucose monitoring (FGM) is quickly becoming a game-changer in diabetes management, offering a more advanced way to track glucose levels throughout the day and night. This innovative technology, a type of continuous glucose monitoring (CGM), allows users to check their glucose levels simply by scanning, providing greater control over how often and when they monitor their glucose.

Recent studies highlight significant improvements in glucose control for patients with severe glucose level fluctuations using FGM technology. Real-world applications show that FGM can reduce both hypoglycemia and hyperglycemia, particularly benefiting high-risk individuals. Notably, Abbott's FreeStyle Libre has demonstrated a positive impact on managing type 1 diabetes, including during pregnancy, while also proving to be a cost-effective alternative to traditional self-monitoring systems.

Abbott’s FreeStyle Libre, launched in 2020, has seen remarkable adoption with over 500,000 users, thanks to its no-fingerstick calibration feature and its 8-hour glucose monitoring capability. The water-resistant sensors, typically worn on the back of the upper arm or abdomen, last between 3 to 14 days. For patients with type 1 and type 2 diabetes, especially those on sulfonylureas or intensive insulin therapy, FGM presents a more economical option compared to traditional blood glucose monitoring and continuous glucose monitoring systems. The expanding patient population and the associated cost benefits signal a promising future for this technology.

 

Watch Out Recent Activities by Market Vendors

  • In 2024, MTD Group acquired the pen needle and blood glucose monitoring systems of Ypsomed, as well as announced significant investment for its European product sites.
  • In 2023, Abbott acquired Bigfoot Biomedical, one of the leading manufacturers of smart insulin management systems. This transaction strengthened Abbott's FreeStyle Libre CGM technology, helping it increase its presence in diabetes care. 
  • In 2023, Medtronic entered into a set of definitive agreement to acquire EoFlow Co. Ltd., a pioneer in insulin delivery devices. Medtronic’s meal detection technology algorithm and next-generation CGM are expected to expand the company’s ability to deliver diabetes care solutions.

 

Product Launched & Development

  • In June 2024, Prevounce Health launched a technologically advanced, cellular-connected blood glucose meter for remote patient monitoring. It is a rigorously tested and FDA-approved device widely available in the US and global markets.
  • In May 2024, Smart Meter launched an iGlucose Plus glucose monitoring device globally. It is a handheld device connected to a smartphone and Wi-Fi systems.
  • In Feb 2024, Dexcom launched Dexcom ONE+, a real-time and customized glucose monitoring device that can be worn in three different body locations. Furthermore, it has a water-resistant sensor that enhances its brand image.

 

Which are the Top Companies in the Blood Glucose Monitoring Devices Market?       

Key Vendors

  • F. Hoffmann-La Roche
  • Abbott
  • Dexcom
  • Medtronic
  • Ascensia Diabetes Care Holdings AG
  • LifeScan IP Holdings
  • Arkray
  • ApexBio
  • ACON Laboratories, Inc.
  • AgaMatrix
  • Alliance International
  • Andon Health
  • Bionime
  • Beurer
  • Bioptik
  • BioTelemetry
  • BioTest Medical
  • BTNX
  • DarioHealth
  • EASYMAX
  • ForaCare
  • Hannox International
  • Integrity Applications
  • i-SENS
  • MED TRUST
  • Medisana
  • Nova Biomedical
  • Omnis Health
  • Nemaura
  • OK Biotech
  • OSANG Healthcare
  • Philosys
  • Sanofi
  • Taidoc Technology
  • Terumo Corporation
  • Trividia Health
  • Rossmax International
  • Ypsomed
  • 77 Electronika Kft
  • Menarini Diagnostics

 

Market Segmentation Overview

Conventional BGM devices, which include test strips, meters, software, and lancet & lancing devices, currently hold the largest market share. Their long-standing use and familiarity in both patient and healthcare settings contribute to their dominance. BGM remains the most prevalent method for monitoring blood glucose, endorsed by health authorities globally. These devices are generally more cost-effective compared to CGM systems, leading to higher adoption rates. The total expense for test strips and BGM devices is significantly lower than that for CGM systems, and the growth of self-monitoring practices further fuels the market for BGM. BGM provides personalized treatment and management for a substantial portion of the diabetes population, offering immediate results that help patients adjust insulin dosages promptly and effectively.

The individual segment is expected to experience the highest growth in the global blood glucose monitoring devices market during the forecast period. Diabetes poses a significant global public health challenge, particularly impacting developing countries where high morbidity and mortality rates are exacerbated by inadequate management and noncompliance with guidelines. Studies reveal that poor diabetes management leads to extremely negative health outcomes, driving diabetic patients to frequently self-test their glucose levels.

Screening large populations for diabetes can be prohibitively expensive and challenging due to the high cost of diagnostic tests and a shortage of healthcare personnel, both in developed and developing countries. In response to these obstacles, patients are increasingly turning to self-monitoring blood glucose devices. Governments and insurance providers are supporting this shift by covering the costs of these devices, further propelling growth in this segment.

 

Segmentation & Forecast

 

Product Type

  • Conventional Blood Glucose Monitoring Devices
  • Continuous Glucose Monitoring (CGM) Devices

 

Conventional Blood Glucose Monitoring Devices

  • Test Strips
  • Meter & Software
  • Lancet & Lancing Devices

 

Continuous Glucose Monitoring (CGM) Devices

  • Sensors
  • Reusable Hardware

 

Usage

  • Personal BGM Devices
  • Professional BGM Devices

 

Distribution Channel

  • Offline
  • Online

 

End-Users

  • Individuals
  • Hospitals & Clinics
  • Other End-users

 

Geography

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • APAC
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Columbia
  • Argentina
  • Middle East & Africa
  • Turkey
  • South Africa
  • Saudi Arabia

 

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the blood glucose monitoring devices market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/blood-glucose-monitoring-devices-market-2024

  

What Key Findings Will Our Research Analysis Reveal? 

How big is the global blood glucose monitoring devices market?

What is the growth rate of the global blood glucose monitoring devices market?

Who are the major players in the global blood glucose monitoring devices market?

Which region dominates the global blood glucose monitoring devices market?

 

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4487

  

Other Related Reports that Might be of Your Business Requirement 

Blood Culture Tests Market - Global Outlook & Forecast 2024-2029

The global blood culture tests market was valued at USD 5.72 billion in 2023 and is expected to reach USD 8.98 billion by 2029, growing at a CAGR of 7.81% during the forecast period. Learn more about the market now: https://www.arizton.com/market-reports/blood-culture-tests-market

Europe Clinical Laboratory Tests Market - Focused Insights 2024-2029

The Europe clinical laboratory tests market size was valued at USD 59.06 billion in 2023 and is expected to reach USD 69.10 billion by 2029, growing at a CAGR of 2.65% during the forecast period. Explore! https://www.arizton.com/market-reports/europe-clinical-laboratory-tests-market

 

Why Arizton?                                            

100% Customer Satisfaction                                            

24x7 availability – we are always there when you need us                                            

200+ Fortune 500 Companies trust Arizton's report                                            

80% of our reports are exclusive and first in the industry                                            

100% more data and analysis                                            

1500+ reports published till date                          

               

Post-Purchase Benefit                                        

  • 1hr of free analyst discussion                                        
  • 10% off on customization                     

              

About Us:                                                                                 

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                               

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                     

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email:Send Email
Phone: +1-312-235-2040 /+1 302 469 0707   
Country: United States
Website: https://www.arizton.com/market-reports/blood-glucose-monitoring-devices-market-2024